FDA Introduces New Safety Measures For Opioids

Whether it be on the street, or at a pain management doctor, if you need a strong pain pill, they are not very difficult to find.  And, today in a society where it is ridiculously easy to access some very strong pain pills, called opioids, the federal government is beginning to worry about the effects they are having on the population that use them.  Therefore the US Food & Drug Administration has just approved a program that seeks to educate and inform about the abuse of opioids.

The FDA has approved a risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioids, the highly potent drugs approved for moderate to severe, persistent pain that requires treatment for an extended period.

The REMS is part of a federal initiative to address the prescription drug abuse, misuse, and overdose epidemic. The REMS introduces new safety measures designed to reduce risks and improve the safe use of ER/LA opioids, while ensuring access to needed medications for patients in pain.

“Misprescribing, misuse, and abuse of extended-release and long-acting opioids are a critical and growing public health challenge,” said FDA Commissioner Margaret A. Hamburg, M.D.  “The FDA’s goal with this REMS approval is to ensure that health care professionals are educated on how to safely prescribe opioids and that patients know how to safely use these drugs.”

Key components of the ER/LA opioid analgesics REMS include: training for providers, an updated guide and patient counseling document and assessment and auditing procedures.

The new ER/LA opioid REMS will affect more than 20 companies that manufacture these opioid analgesics. Under the new REMS, companies will be required to make education programs available to prescribers based on an FDA Blueprint. It is expected that companies will meet this obligation by providing educational grants to continuing education (CE) providers, who will develop and deliver the training.

The REMS also will require companies to make available FDA-approved patient education materials on the safe use of these drugs. The companies will be required to perform periodic assessments of the implementation of the REMS and the success of the program in meeting its goals. The FDA will review these assessments and may require additional elements to achieve the goals of the program.

ER/LA opioid analgesics are associated with serious risks of overuse, abuse, misuse and death and the numbers continue to rise. According to the Centers for Disease Control and Prevention, 14,800 Americans died from overdoses involving opioids in 2008. In 2009, there were 15,597 deaths involving these medications – nearly four times as many deaths compared to 1999.

“We commend the FDA for taking action to save lives by increasing access to prescriber education,” said Gil Kerlikowske, director of the Office of National Drug Control Policy.

“Misuse and abuse of prescription opioids is a complex problem and demands a holistic response,” said John Jenkins, M.D., director of CDER’s Office of New Drugs. “The new REMS program is one component of a multi-agency, national strategy to address this important public health issue.”



,

2 Responses to FDA Introduces New Safety Measures For Opioids

  1. David Allen August 6, 2012 at 9:08 am #

    I was prescribed oxycodone from 2005-2011 (200mg daily) and switched to Morphine Sulfate ER and IR in March of 2011 of which I now take 360mg daily for degenerative disc disease.

    I still had a few of the oxy left over from 2011 and in May used them – IN PLACE OF- my 100mg MS for a few days sue to a bout of very increased pain. It came back in my May urine test.

    My doctor never said to not take these in place of the MS, after much talk of the MS not being as effective. Nor did he give me any form of info on how to properly dispose of the oxy. Now all hell has hit the fan because of the urine test and they are threatening to drop me as a patient.

    I feel he and the clinic are putting me in great risk of detoxing if they are to simply cut me off without any transformation process.

    I have NEVER abused the RX and always taken as prescribed. I do not feel it is safe for the patient to be left on the hook like that. Were he to cut me off, I would have serious side effects, not to mention debilitating pain.

    How can physicians who take an oath of “no harm” get away with such behavior?

    Sincerely D. Allen

    • Drug Recall Lawyer August 6, 2012 at 9:36 am #

      It is terrible that some physicians get away with opening and maintaining “pill factories”. It is a serious problem not only with pain management, but also with drugs used to treat mental illness. Most physicians now leave psychological therapy to others while all they do is prescribe. Our health care system is seriously broken.

Leave a Reply

GET HELP NOW!
  • This field is for validation purposes and should be left unchanged.
Latest Drug Injury News

Underground Railway Dust May Pose Health Risk

Travelling or working on an underground railway for sustained period of time could have health implications due to concentrations of metal-rich microscopic dust particles.

New Study Helps Understand Why Health Care Costs On The Rise

Although many believe is it medical malpractice suites that are causing the increase in the health care costs, it is actually the fear of them that is partly to blame. Doctors are ordering unnecessary tests and procedures for fear of a patient filing a claim down the road

FDA Issues New Warnings Concerning Tolvaptan

The FDA has issued a drug safety communication concerning Tolvaptan, a selective vasopression V2-receptor antagonist used in heart failure patients to treat clinically significant hypervolemic and euvolemic hyponatremia.

New Antiepileptic Drug Causes Blue Discoloration And Vision Trouble

An antiepileptic drug to hit the market has been known to cause vision troubles and skin discoloration. Almost all patients experienced gray/blue skin discoloration who had been taking the pill for two years. More information is needed to better understand the occurrences.

Medical Mattresses Pose Risk Of Infection And Contamination

The FDA warns that medical mattresses may not be as clean as once perceived. Routine checks on mattresses are advised as any rips, tears, or excessive wear alter the efficacy. The medical mattresses as well as the covers have an expected life depending on the manufacturer, which should not go unnoticed.

Latest Medical Device Injury News

Women 30% More Likely To Need Repeat Hip Implant Surgery

Doctors traditionally believed the larger the size of the implant, the more protective it was against failure, according to Sedrakyan. However, he said his study found regardless of size, women had a higher rate of revision occurrence, so some other factor besides the actual implants may be leading to this effect.

Transvaginal Mesh Lawsuits – Who Is At Fault?

For some women a pelvic transvaginal mesh product has been a god sent.  To be able to resume a full active life, without the worry of a leaky bladder, is a true miracle for some women.  And, this only became possible with the help of pelvic mesh. The mesh is most commonly used after pelvic [...]

Metal-on-Metal Hip Implants Cause Soft Tissue Damage Says FDA

Hip joint deterioration can lead to pain, stiffness or difficulty walking. When these symptoms do not respond to conservative treatment, such as physical therapy, patients may be advised to undergo total hip replacement or hip resurfacing. As part of this treatment, they may receive a “metal-on-metal” hip implant in which the “ball and socket” of [...]

Ethicon Recalls Surgical Stapler

The FDA has announced a voluntary global recall of more than 157,000 Ethicon surgical staplers, due to problems with incomplete firing strokes that may cause faulty staple formation, potentially resulting in painful and severe internal complications for the patient. An Ethicon surgical stapler recall was first announced in August, after reports surfaced where surgeons experienced [...]

Another Device Maker Investigated By DOJ

Earlier this month, cardiovascular device maker Abiomed announced that the US Attorney’s Office was investigating the company’s marketing and labeling of the Impella 2.5 circulatory support device. According to Forbes, the announcement confirmed rumors that had been circulating for at least two weeks, though in the press release the company said it had just been [...]